Company Encyclopedia
View More
name
Chesnara Plc
CSN.UK
News
View More

REG - FTSE Russell Primary Health Props Assura plc Chesnara PLC - Primary Health Properties

FTSE Russell announced changes to the FTSE UK Index Series effective 18 August 2025. Primary Health Properties will remain in the FTSE 250 Index, while Assura will be removed. Chesnara will be added to the FTSE 250 Index and removed from the FTSE SmallCap Index. The changes follow the unconditional offer for Assura by Primary Health Properties. For more details, visit the FTSE Russell website or contact their client services.

London Stock Exchange·
UK
CSN
0.00%
UK
AGR
0.00%
London Stock Exchange·
UK
CSN
0.00%
UK
AGR
0.00%

Chesnara Successfully Completes Rump Placing Following Rights Issue

Chesnara PLC has successfully completed its rump placing following a rights issue, securing subscribers for all unaccepted New Ordinary Shares at 255 pence per share. This move enhances the company's financial stability and market position. The latest analyst rating for Chesnara stock (GB:CSN) is a Buy with a £320.00 price target, although Spark's AI Analyst rates it as Neutral due to high valuation concerns despite a strong dividend yield. Chesnara operates in the financial services sector, focusing on life insurance and pension products.

Tip Ranks·
UK
CSN
0.00%
Tip Ranks·
UK
CSN
0.00%

REG - Chesnara PLC - Director/PDMR Shareholding

Chesnara PLC announced that several PDMRs acquired ordinary shares through a rights issue on July 23, 2025. Steven Murray acquired 132,019 shares, increasing his indirect interest to 382,858 shares. Other notable acquisitions include Tom Howard (13,907 shares), Luke Savage (15,789 shares), Eamonn Flanagan (15,789 shares), and Carol Hagh (15,789 shares), all through the same rights issue at a price of 176p per share. The transactions took place on the London Stock Exchange.

London Stock Exchange·
UK
CSN
0.00%
London Stock Exchange·
UK
CSN
0.00%

Chesnara PLC Announces £140 Million Rights Issue

Chesnara PLC has announced a £140 million rights issue, approved by the FCA, aimed at strengthening its capital base and supporting strategic growth initiatives. The latest analyst rating for Chesnara stock (GB:CSN) is a Buy with a price target of £320.00, although TipRanks’ AI Analyst rates it as Neutral due to potential overbought conditions. Chesnara operates in the financial services sector, focusing on life insurance and pension management, with a current market cap of £454.9 million.

Tip Ranks·
UK
CSN
0.00%
Tip Ranks·
UK
CSN
0.00%

REG - Chesnara PLC - Publication of a Prospectus

Chesnara PLC has published a prospectus approved by the FCA in connection with its rights issue aimed at raising approximately £140 million. The prospectus will be sent to shareholders who opted for hard copies on July 4, 2025, and will also be available on the company's website. This announcement serves as an advertisement under the UK Prospectus Regulation Rules and does not constitute a prospectus or an inducement to enter into any contract. Investors are advised to rely solely on the information contained in the prospectus for any decisions regarding the rights issue.

London Stock Exchange·
UK
CSN
0.00%
London Stock Exchange·
UK
CSN
0.00%